Biogen (BIIB) net income: $1.3B
Biogen reported a net income of $1.3B for the year ended Dec 31, 2025, down 20.8% from $1.6B a year earlier.
From Biogen's filings with the SEC · Read the filing · BIIB stock page
Biogen net income by year
#308 of 3,748 US companies by net income · See the full ranking
| Year ended | Net income | Change |
|---|---|---|
| Dec 31, 2025 | $1.3B | -21% |
| Dec 31, 2024 | $1.6B | +41% |
| Dec 31, 2023 | $1.2B | -62% |
| Dec 31, 2022 | $3B | +96% |
| Dec 31, 2021 | $1.6B | – |
Net income of similar companies
Companies in the same industry as Biogen, by SEC industry code, with the closest net income. Each name opens the same page for that company.
| Company | Net income, latest year | Year ended |
|---|---|---|
| Biogen | $1.3B | Dec 31, 2025 |
| Exelixis | $783M | Jan 2, 2026 |
| Neurocrine Biosciences | $479M | Dec 31, 2025 |
| Novavax | $440M | Dec 31, 2025 |
| Qiagen | $425M | Dec 31, 2025 |
| Halozyme Therapeutics | $317M | Dec 31, 2025 |
| Biocryst Pharmaceuticals | $264M | Dec 31, 2025 |
Questions and answers
What is Biogen's net income?
Biogen reported a net income of $1.3B for the year ended Dec 31, 2025, down 20.8% from $1.6B a year earlier.
Numbers as reported in Biogen's annual and quarterly reports to the SEC (XBRL data). A year is the company's fiscal year that falls mostly in that calendar year; balances such as cash and debt are as of the date shown. Data only, not investment advice. Methodology